FacebookTwitterRedditEmail

It’s the Cymbalta Stupid

Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to “educate” doctors about the pain-and-fatigue ailment fibromyalgia–more than it spent for diabetes and Alzheimer’s which people already know they have.

But finding new diseases to justify a drug’s existence is the normal way pharma operates.

Especially Lilly who agreed to pay $1.42 billion for illegal marketing of its anti-psychotic Zyprexa last month–$615 million for criminally promoting it for dementia–another $62 million to 32 states for illegal pediatric marketing and agreed to resolve Medicaid fraud investigations into “rebates” at the same time. (And how was your year?)

And whose diabetes treatment Byetta is tanking since reports last summer of six deaths, at least two from pancreatitis.

But Lilly’s fibromyalgia-fighting drug, Cymbalta (duloxetine)–its second best seller after Zyprexa–is anything but normal.

Starting with the death of 19-year-old Cymbalta test subject Traci Johnson in 2004–who hanged herself in the Lilly Clinic in Indianapolis and had no history of mental problems–it has been beset by reports of baffling, rapid, unprovoked, and out of character suicides and suicide attempts.

A 37-year-old man described in the Feb. 2008 Journal of Clinical Psychopharmacology with a stable marriage and employment and no history of mental problems tried to kill himself with carbon monoxide two months after taking Cymbalta for back pain. “The patient was unable to state exactly why he wanted to commit suicide,” write the four physician authors all with the Department of Psychiatry and Behavioral Sciences at the University of Kansas Medical Center who note he returned to normal when the drug was stopped.

A 63-year-old man with no history of suicide attempts or ideation was similarly “unable to explain why he was having thoughts of wanting to die,” say the authors after becoming suicidal two weeks after being put on Cymbalta for fatigue, insomnia and sadness.

Last January, a Texas man prescribed Cymbalta for peripheral neuropathy because of a job that required him to be on his feet all day with no history mental problems “had a normal day at work, drove home, said he was going to grab a sandwich to his wife, and went and shot himself,” his family wrote a reporter.

In Feb. 2007, a 19-year-old Wisconsin college student recently put on Cymbalta “checked out books for a paper he was to write over the weekend,” emailed his resume “to see if he could get a spot on Obama’s team for the summer” and “then hung himself from his loft bed in his dorm,” writes his family. One month earlier, a 21-year old Midwest college student, recently put on Cymbalta, took his own life three minutes after speaking to his family while driving home and sounding fine, the family wrote a reporter.

Nor are incomprehensible and abrupt suicide attempts on Cymbalta a US phenomenon.

Doctors Bilal Salem and Elie Karam of the Saint George Hospital University Medical Center in Beirut, Lebanon write of similar “suicidality in apparently nonsuicidal patients after starting or increasing Duloxetine,” in the June 2008 Clinical Practice and Epidemiology in Mental Health.

Approved as an antidepressant and for diabetic nerve pain in 2004–soon after the Johnson suicide thanks to an unfazed FDA–Cymbalta soon proved to be the “Swiss Army Knife” of Lilly drugs says its hometown paper the Indianapolis Star–approved for general anxiety disorder and maintenance treatment of depression in 2007, for fibromyalgia in 2008 and with approvals for chronic knee and low back pain expected shortly.

In Europe it is in use for stress urinary incontinence but in the US its side effect of urinary retention landed Cymbalta on the FDA’s first Potential Signals of Serious Risks danger list in 2008. (FDA won’t release suicidal rates from stress urinary incontinence trials says reporter Jeanne Lenzer on Slate, who estimates them as 400 per 100,000 person-years for middle aged women.)

But some, like Shannon Brownlee, author of “Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer,” question the revenue-driven prescribothan. Should drugs “that may have a really serious side effect called suicide,” be used for simple knee or back pain, she asks in the Star.

No kidding! Cymbalta is also being studied for binge eating, social phobia, chronic fatigue, restless legs disorder, seasonal affective disorder, migraines, attention deficit disorder and childhood depression–despite known pediatric risks–PMS, menopause, alcoholism, panic disorder, obsessive compulsive disorder, kleptomania and the important medical condition: tennis elbow.

At the American Academy of Pain Medicine Annual Meeting in January, Lilly presented a study by its own doctors finding Cymbalta was superior to placebo in knee pain–in keeping with its penchant to publish studies by Lilly funded and Lilly employed doctors saying Cymbalta is safe.

Cymbalta is also a good use of state and third party payer dollars say Lilly funded doctors in “Differences In Medication Adherence and Healthcare Resource Utilization Patterns: Older Versus Newer Antidepressant Agents In Patients With Depression And/Or Anxiety Disorders” in the 2008-22 CNS Drugs who are fighting the “restrictive reimbursement policies for newer antidepressants,” in which pharmacy benefits managers are saying you want us to spend WHAT?

Getting benefits managers to cover the $200 a month cost for Cymbalta prescriptions for fibromyaglia may also be tough since the ailment has no clear cause, blood test or cure. Maybe Lilly will offer pointers in the medical courses it is funding.

MARTHA ROSENBERG is a columnist/cartoonist who writes about public health. She can be reached at: mrosenberg@evmark.org

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
Weekend Edition
December 13, 2019
Friday - Sunday
Melvin Goodman
The FBI: Another Worry in the National Security State
Rob Urie
Establishment Politics are for the Rich
Jeffrey St. Clair
Roaming Charges: That’s Neoliberalism for You
Paul Street
Midnight Ramble: A Fascist Rally in Hershey, Pennsylvania
Joan Roelofs
The Science of Lethality
Joyce Nelson
Buttigieg and McKinsey
Joseph Natoli
Equally Determined: To Impeach/To Support
Charles Pierson
The National Defense Authorization Act Perpetuates the Destruction of Yemen
REZA FIYOUZAT
An Outrageous Proposal: Peace Boats to Iran
Lee Hall
Donald Trump Jr., Mongolian Sheep Killer
Andrew Levine
A Plague on Both Their Houses, Plus a Dozen Poxes on Trump’s
David Rosen
Mortality Rising: Trump and the Death of the “American Dream”
Dave Lindorff
The Perils of Embedded Journalism: ‘Afghan Papers’ Wouldn’t Be Needed If We Had a Real Independent News Media
Brian Cloughley
Human Rights and Humbug in Washington
Stephen Leas
Hungry for a Livable Planet: Why I Went On Hunger Strike and Occupied Pelosi’s Office
Saad Hafiz
Pakistan Must Face Its Past
Lawrence Davidson
Deteriorating Climates: Home and Abroad
Cal Winslow
The End of the Era: Nineteen Nineteen
Louis Proyect
If Time Magazine Celebrates Greta Thunberg, Why Should We?
Thomas Drake
Kafka Down Under: the Threat to Whistleblowers and Press Freedom in Australia
Thomas Knapp
JEDI Mind Tricks: Amazon Versus the Pentagon and Trump
Jesse Jackson
Trump’s War on the Poor
Michael Welton
Seeing the World Without Shadows: the Enlightenment Dream
Ron Jacobs
The Wind That Shook the Barley: the Politics of the IRA
Rivera Sun
Beyond Changing Light Bulbs: 21 Ways You Can Stop the Climate Crisis
Binoy Kampmark
The Bloomberg Factor: Authoritarianism, Money and US Presidential Politics
Nick Pemberton
Ideology Shall Have No Resurrection
Rev. Susan K. Williams Smith
What Trump and the GOP Learned From Obama
Ramzy Baroud
‘Elected by Donors’: the University of Cape Town Fails Palestine, Embraces Israel
Cesar Chelala
Unsuccessful U.S. Policy on Cuba Should End
Harry Blain
The Conservatism of Impeachment
Norman Solomon
Will the Democratic Presidential Nomination Be Bought?
Howard Lisnoff
The One Thing That US Leaders Seem to Do Well is Lie
Jeff Cohen
Warren vs. Buttigieg Clash Offers Contrast with Sanders’ Consistency
Mel Gurtov
The Afghanistan Pentagon Papers
Gaither Stewart
Landslide … to Totalitarianism
Kollibri terre Sonnenblume
How Blaming Nader in 2000 Paved the Way for Today’s Neo-Fascism
Steve Early
In Re-Run Election: LA Times Journalist Wins Presidency of NewsGuild 
David Swanson
If You’re Not Busy Plotting Nonviolent Revolution for Peace and Climate, You’re Busy Dying
Nicky Reid
Sorry Lefties, Your Impeachment is Bullshit
John Kendall Hawkins
The Terror Report You Weren’t Meant to See
Susan Block
Krampus Trumpus Rumpus
Martin Billheimer
Knight Crawlers
David Yearsley
Kanye in the West
Elliot Sperber
Dollar Store 
FacebookTwitterRedditEmail